Literature DB >> 24429431

A multicenter study of initiation of antiretroviral therapy and transmitted drug resistance in antiretroviral-naive adolescents and young adults with HIV in New York City.

Christina Gagliardo1, Ava Brozovich, Jeffrey Birnbaum, Anita Radix, Marc Foca, John Nelson, Lisa Saiman, Michael Yin, Elektra Carras-Terzian, Emily West, Natalie Neu.   

Abstract

BACKGROUND: In December 2009, the Department of Health and Human Services guidelines for initiation of antiretroviral therapy (ART) changed to include patients with CD4 counts between 350 and 500 cells/µL. The aims of this study were to assess uptake of this recommendation in ART-naive youth with human immunodeficiency virus (HIV) and to describe the epidemiology of transmitted genotypic drug resistance mutations (DRMs) in this population.
METHODS: A multicenter, retrospective cohort study of ART initiation in ART-naive youth was performed. Eligible subjects were 13-25 years of age, were diagnosed with HIV within 1 year of presentation to care at the study sites, and presented to care from January 2007 to June 2011.
RESULTS: Of 685 potential subjects identified, 331 (49%) fulfilled inclusion criteria. Mean CD4 count at presentation to care was 452 cells/µL. Overall, 191 (58%) subjects started ART. The mean CD4 count at ART initiation was 261 cells/µL before and 363 cells/µL after the 2009 guideline change (P < .0001). Of 212 (64%) subjects with resistance testing available prior to ART initiation, 38 (18%) subjects had a major DRM and an increased proportion of resistance was seen in later study years.
CONCLUSIONS: Our study demonstrated an uptake in recently changed guideline recommendations to treat HIV-infected individuals at higher CD4 counts and reinforces the importance of performing resistance testing at entry into care, as 18% of our population had major DRMs prior to initiation of ART.

Entities:  

Keywords:  HIV; adolescents; antiretroviral therapy; genotypic resistance; youth

Mesh:

Substances:

Year:  2014        PMID: 24429431      PMCID: PMC3988426          DOI: 10.1093/cid/ciu003

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  34 in total

1.  Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy.

Authors:  Michela Violin; Alessandro Cozzi-Lepri; Rossella Velleca; Antonella Vincenti; Salvatore D'Elia; Francesco Chiodo; Florio Ghinelli; Ada Bertoli; Antonella d'Arminio Monforte; Carlo Federico Perno; Mauro Moroni; Claudia Balotta
Journal:  AIDS       Date:  2004-01-23       Impact factor: 4.177

2.  Prevalence of primary HIV-1 drug resistance among recently infected adolescents: a multicenter adolescent medicine trials network for HIV/AIDS interventions study.

Authors:  Rolando M Viani; Ligia Peralta; Grace Aldrovandi; Bill G Kapogiannis; Rick Mitchell; Stephen A Spector; Yolanda S Lie; Jodi M Weidler; Michael P Bates; Nancy Liu; Craig M Wilson
Journal:  J Infect Dis       Date:  2006-10-20       Impact factor: 5.226

3.  Prevalence of antiretroviral drug resistance and resistance-associated mutations in antiretroviral therapy-naïve HIV-infected individuals from 40 United States cities.

Authors:  Lisa Ross; Michael L Lim; Qiming Liao; Brian Wine; Allan E Rodriguez; Winkler Weinberg; Mark Shaefer
Journal:  HIV Clin Trials       Date:  2007 Jan-Feb

4.  Survival of persons with and without HIV infection in Denmark, 1995-2005.

Authors:  Nicolai Lohse; Ann-Brit Eg Hansen; Gitte Pedersen; Gitte Kronborg; Jan Gerstoft; Henrik Toft Sørensen; Michael Vaeth; Niels Obel
Journal:  Ann Intern Med       Date:  2007-01-16       Impact factor: 25.391

5.  Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group.

Authors:  T C Quinn; M J Wawer; N Sewankambo; D Serwadda; C Li; F Wabwire-Mangen; M O Meehan; T Lutalo; R H Gray
Journal:  N Engl J Med       Date:  2000-03-30       Impact factor: 91.245

6.  Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons.

Authors:  J G Garcia-Lerma; S Nidtha; K Blumoff; H Weinstock; W Heneine
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-06       Impact factor: 11.205

7.  Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team.

Authors:  L M Mofenson; J S Lambert; E R Stiehm; J Bethel; W A Meyer; J Whitehouse; J Moye; P Reichelderfer; D R Harris; M G Fowler; B J Mathieson; G J Nemo
Journal:  N Engl J Med       Date:  1999-08-05       Impact factor: 91.245

8.  Changes in the risk of death after HIV seroconversion compared with mortality in the general population.

Authors:  Krishnan Bhaskaran; Osamah Hamouda; Mette Sannes; Faroudy Boufassa; Anne M Johnson; Paul C Lambert; Kholoud Porter
Journal:  JAMA       Date:  2008-07-02       Impact factor: 56.272

9.  The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities.

Authors:  Hillard S Weinstock; Irum Zaidi; Walid Heneine; Diane Bennett; J Gerardo Garcia-Lerma; John M Douglas; Marlene LaLota; Gordon Dickinson; Sandra Schwarcz; Lucia Torian; Deborah Wendell; Sindy Paul; Garald A Goza; Juan Ruiz; Brian Boyett; Jonathan E Kaplan
Journal:  J Infect Dis       Date:  2004-05-21       Impact factor: 5.226

10.  1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults.

Authors: 
Journal:  MMWR Recomm Rep       Date:  1992-12-18
View more
  7 in total

1.  Antiretroviral treatment failure, drug resistance, and subtype diversity in the only pediatric HIV clinic in Rhode Island.

Authors:  Tanya Rogo; Allison K DeLong; Philip Chan; Rami Kantor
Journal:  Clin Infect Dis       Date:  2015-01-30       Impact factor: 9.079

2.  Impact of low-level viremia with drug resistance on CD4 cell counts among people living with HIV on antiretroviral treatment in China.

Authors:  Pengtao Liu; Yinghui You; Lingjie Liao; Yi Feng; Yiming Shao; Hui Xing; Guanghua Lan; Jianjun Li; Yuhua Ruan; Dan Li
Journal:  BMC Infect Dis       Date:  2022-05-04       Impact factor: 3.667

Review 3.  Prevention of human immunodeficiency virus and AIDS: postexposure prophylaxis (including health care workers).

Authors:  Susan E Beekmann; David K Henderson
Journal:  Infect Dis Clin North Am       Date:  2014-10-05       Impact factor: 5.982

4.  Comparing longitudinal CD4 responses to cART among non-perinatally HIV-infected youth versus adults: Results from the HIVRN Cohort.

Authors:  Allison L Agwu; John A Fleishman; Guy Mahiane; Bareng Aletta Sanny Nonyane; Keri N Althoff; Baligh R Yehia; Stephen A Berry; Richard Rutstein; Ank Nijhawan; Christopher Mathews; Judith A Aberg; Jeanne C Keruly; Richard D Moore; Kelly A Gebo
Journal:  PLoS One       Date:  2017-02-09       Impact factor: 3.240

5.  Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted Human Immunodeficiency Virus Type 1 Drug Resistance in a Large US Clinic Population.

Authors:  Soo-Yon Rhee; Dana Clutter; W Jeffrey Fessel; Daniel Klein; Sally Slome; Benjamin A Pinsky; Julia L Marcus; Leo Hurley; Michael J Silverberg; Sergei L Kosakovsky Pond; Robert W Shafer
Journal:  Clin Infect Dis       Date:  2019-01-07       Impact factor: 9.079

6.  Prevalence and trends in transmitted and acquired antiretroviral drug resistance, Washington, DC, 1999-2014.

Authors:  Annette M Aldous; Amanda D Castel; David M Parenti
Journal:  BMC Res Notes       Date:  2017-09-11

7.  HIV-1 Drug Resistance, Distribution of Subtypes, and Drug Resistance-Associated Mutations in Virologic Failure Individuals in Chengdu, Southwest China, 2014-2016.

Authors:  Jiayi Chen; Yang Liu; Sijing Liu; Dan Yuan; Ling Su; Li Ye; Fanghong Gong; Yushuang Gao; Saira Baloch; Xiaofang Pei
Journal:  Biomed Res Int       Date:  2020-03-23       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.